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A multiple myeloma-speciﬁc capture
sequencing platform discovers novel
translocations and frequent, risk-associated
point mutations in IGLL5
Brian S. White1,5, Irena Lanc1, Julie O’Neal1, Harshath Gupta1, Robert S. Fulton2, Heather Schmidt2, Catrina Fronick2,
Edward A. BelterJr.2, Mark Fiala1, Justin King1, Greg J. Ahmann3, Mary DeRome4, Elaine R. Mardis2,6, Ravi Vij1,
John F. DiPersio1, Joan Levy4,8, Daniel Auclair4 and Michael H. Tomasson1,7
Abstract
Multiple myeloma (MM) is a disease of copy number variants (CNVs), chromosomal translocations, and single-
nucleotide variants (SNVs). To enable integrative studies across these diverse mutation types, we developed a capture-
based sequencing platform to detect their occurrence in 465 genes altered in MM and used it to sequence 95 primary
tumor-normal pairs to a mean depth of 104×. We detected cases of hyperdiploidy (23%), deletions of 1p (8%), 6q
(21%), 8p (17%), 14q (16%), 16q (22%), and 17p (4%), and ampliﬁcation of 1q (19%). We also detected IGH and MYC
translocations near expected frequencies and non-silent SNVs in NRAS (24%), KRAS (21%), FAM46C (17%), TP53 (9%),
DIS3 (9%), and BRAF (3%). We discovered frequent mutations in IGLL5 (18%) that were mutually exclusive of RAS
mutations and associated with increased risk of disease progression (p= 0.03), suggesting that IGLL5 may be a
stratifying biomarker. We identiﬁed novel IGLL5/IGH translocations in two samples. We subjected 15 of the pairs to
ultra-deep sequencing (1259×) and found that although depth correlated with number of mutations detected (p=
0.001), depth past ~300× added little. The platform provides cost-effective genomic analysis for research and may be
useful in individualizing treatment decisions in clinical settings.
Introduction
Multiple myeloma (MM) is a fatal malignancy of mature
plasma B cells. Overt MM is preceded by a premalignant
phase, monoclonal gammopathy of undetermined sig-
niﬁcance (MGUS), which can progress to smoldering MM
and ultimately to fatal myeloma. Genetic alterations
detected in premalignant MGUS cells are likely initiating
events. These may be divided into two primary subtypes
that are most often non-overlapping1: hyperdiploid (HRD)
myeloma is characterized by trisomies of most odd-
numbered chromosomes2, while non-HRD myeloma fre-
quently involves immunoglobulin heavy chain (IGH)
translocations. These upregulate target oncogenes by
placing them under the control of one or both of the
powerful, B-cell-speciﬁc IGH enhancer regions; canonical
IGH partner genes include WHSC1/FGFR3, CCND3,
CCND1, MAF, and MAFB in translocations t(4;14), t
(6;14), t(11;14), t(14;16), and t(14;20), respectively1. Sec-
ondary genetic events are detected in MM, but not its
precursor phases, and are thought to drive disease pro-
gression. The most prevalent secondary events include
MYC translocations (juxtaposing IGH and other loci),
single-nucleotide variants (SNVs) involving KRAS, NRAS,
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and DIS3, and copy number variants (CNVs) that amplify
chromosome arm 1q or delete 1p, 6q, 13, 14q, or 16q2.
This diversity of genetic lesions has recently been
leveraged in a prognostic model that integrates the
International Staging System (ISS)3 with incidence of
CNVs, SNVs, and translocations4. This ISS-MUT model
increases precision over ISS alone in detecting early
mortality and progression. Other studies have highlighted
the context-dependent prognostic signiﬁcance of variants
across the spectrum of mutation types1. For example,
trisomies of chromosomes 3 or 5 have been found to
abrogate the poor overall survival associated with t(4;14)
translocations5. Collectively, these results highlight the
prognostic impact of the interplay between CNVs, SNVs,
and translocations—the potential for co-occurring muta-
tions to mitigate an otherwise poor outcome implies that
testing a patient for all three types of mutations may help
target chemotherapy regimens more accurately to speciﬁc
patient subgroups in the future2.
Detecting myeloma-relevant mutations may be done via
exome sequencing, as in the ISS-MUT study4. However,
approaches targeting a subset of disease-associated genes
should reduce computational analysis, facilitate quicker
return of clinical results, and enable deeper sequencing at
a ﬁxed budget6. Indeed, targeted, clinical sequencing is
performed with increasing frequency both commercially7
and through cancer centers8–10. In the speciﬁc context of
MM, an amplicon-based, 77-gene panel detects both
CNVs and SNVs11. This extends an earlier panel6 used to
track mutation evolution across 47 genes12. Other efforts
have focused on IGH rearrangements and translocations:
amplicon-based sequencing of the locus effectively detects
minimal residual disease13, while capture-based approa-
ches have been used to discover IGH and MYC
translocations14,15.
Similar enrichment technologies could be used to
simultaneously detect CNVs, SNVs, and translocations.
Indeed, one such platform was recently described—the
approach involved targeted sequencing of the IGH locus
and 246 genes implicated in MM and/or other cancers16.
The platform was used to proﬁle 14 MM cell lines and ﬁve
primary samples. Maturing such approaches will require
extensive validation and tuning of the associated bioin-
formatics methods. Towards this end, we developed a
related MM-speciﬁc targeted sequencing platform and
validated it against 95 primary tumor samples, 44 of
which were previously subjected to exome sequencing
and 22 of which were previously assayed by ﬂuorescence
in situ hybridization (FISH). We demonstrate high con-
cordance of the platform with these exome sequencing
and FISH results. Additionally, we describe novel
approaches to tuning computational CNV and translo-
cation calling methods. These optimized methods facili-
tated integrative analysis across mutation types, which
revealed patterns of mutual exclusivity and co-occurrence
involving CNVs, SNVs, and translocations. We discovered
novel translocations juxtaposing IGLL5 with IGH and
detected high-frequency mutations in IGLL5. These
IGLL5 mutations were mutually exclusive of RAS muta-
tions and associated with disease progression, suggesting
that IGLL5 may be involved in disease pathogenesis and/
or serve as a biomarker of high-risk MM.
Methods
We designed a Nimblegen probe set (Roche) targeting
3.3Mb of space that includes 465 genes and the IGH
region. Sequencing library pools were prepared, hybri-
dized to the probes, and sequenced on the HiSeq2000
(2 × 100 reads for initial sequencing of 95 tumor-normal
pairs) or the HiSeq2500 (2 × 125 reads for deep sequen-
cing of a subset of 15 pairs). Reads were aligned against
human reference genome GRCh37-lite using BWA17.
Acquired SNVs were called in each tumor sample relative
to its paired normal sample using samtools18, Soma-
ticSniper19, MuTect20, Strelka21, and VarScan2 (ref. 22).
Translocations were called using LUMPY23, with results
ﬁltered by a machine learning approach optimized to
achieve high precision relative to available FISH results.
CNVs were called using CopyCAT2 (https://github.com/
abelhj/cc2/; ref.24) parameterized to detect copy number
alterations exceeding the level of noise estimated from
diploid regions using a gaussian mixture model (https://
github.com/genome/bmm). Additional information is
provided in Supplementary Methods.
Results
We developed a MM-speciﬁc custom capture sequen-
cing platform capable of detecting CNVs, SNVs, and
translocations. We designed oligonucleotide probes cov-
ering 3.3Mb of genomic space and complementary to the
exons, untranslated regions, and splice sites of 465 genes
(Tables S1 and S2) expressed in MM that: (1) are anno-
tated as cancer genes (in COSMIC25 or MutSig26), (2)
function in DNA repair or B-cell biology, (3) are mutated
at a frequency of >3% in published studies27,28, or (4) have
mutations that cluster in hotspots. To detect IGH trans-
locations, we also designed probes tiled in an unbiased
manner across the locus, including within the variable
(IGHV), diversity (IGHD), joining (IGHJ), and constant/
switch regions. We also designed probes targeting the
exonic regions of canonical IGH translocation partners
(CCND1, CCND3, FGFR3, MAF, MAFB, WHSC1, and
WWOX). To capture secondary MYC translocations, we
tiled probes across exonic and intronic regions of the
MYC locus.
We used the platform to sequence DNA isolated from
95 tumor (CD138-puriﬁed cells isolated from bone mar-
row aspirates) and paired normal (blood) samples. These
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samples were speciﬁcally selected to validate our platform
and to tune our computational methods as a subset of them
were previously subjected to exome sequencing (44 sam-
ples) and/or FISH (22 samples) analysis of IGH transloca-
tions. We achieved a mean sequencing depth of 104× (min
= 33×, max= 140×; Supplementary Figure S1A) across the
tumor samples and of 107× (min= 43×, max= 168×;
Supplementary Figure S1B) across the normal samples.
Targeted capture sequencing identiﬁes copy number
alterations with prognostic signiﬁcance
The broad coverage of the platform [across chromo-
some arms (Table S3) and 465 genes] facilitated detection
of chromosome-level, arm-level, and focal CNVs. We
identiﬁed these events computationally from the per-
probe ratios of tumor to normal sequencing depth using
CopyCAT2 (ref.24). To reduce false positives, we devel-
oped an approach that ﬁltered CNV calls with ratios
below a noise level estimated from diploid regions (Sup-
plementary Figure S2A–C). Our approach identiﬁed the
full range of CNVs, from genome-scale hyperdiploid
events (Fig. 1a; Table S4) to focal events, including a
homozygous deletion that encompassed BRCA2 (Fig. 1b).
Detected arm-level events included those associated with
poor prognosis such as amp(1q), del(1p), del(13q), and del
(17p) (reviewed in ref.1; Supplementary Figure S2D).
Targeted capture sequencing identiﬁes IGH translocations
We detected IGH translocations using LUMPY and
again developed a ﬁltering strategy to reduce likely false
positives. We ﬁltered putative translocations based on
thresholds on the number of supporting split reads and
discordant paired-end reads. We tuned the thresholds to
maximize precision using a machine learning approach
and available FISH data, resulting in a precision of 100%
and a recall of 64% (Supplementary Figure S3; Supple-
mentary Table S5). Canonical IGH translocations were
then detected by the platform near expected frequencies
(Table 1; Fig. 2a) and occurred predominantly within the
IGH constant region, but also telomeric of the IGHM
switch region and occasionally within the D and J regions
(Fig. 2c). Notably, one of the t(11;14) translocations
occurred within the constant region, but outside all
constant and switch segments. These results are con-
sistent with a recent study15, which found IGH translo-
cations occurring within each of these regions. No
translocations within the V region passed the ﬁltering
step.
IGLL5 is translocated and co-incident with overexpression
of DERL3 in multiple myeloma
To prioritize novel IGH translocations as potential
driver mutations, we identiﬁed cancer-associated genes
within 1Mb of each chromosomal breakpoint (Supple-
mentary Table S6). The two annotated translocations with
largest total evidence (sum of number of supporting split
reads and number of discordant paired-end reads) were
analyzed further. The ﬁrst was a complex translocation
involving chromosomes 11, 13, and 14. The putative
breakpoint on chromosome 13 was nearby FLT3
(<0.5Mb; Supplementary Figure S4); we validated that
chromosome 13q12.2 was indeed translocated to IGH on
chromosome 14 using PCR.
Breakpoints of the second highly-supported transloca-
tion, t(14,22)(q32.33;q11.22), were located within IGH and
IGLL5, which is spanned by the immunoglobulin lambda
light chain locus (Fig. 3a). To validate this translocation,
we performed PCR ampliﬁcation of the putative break-
point on DNA isolated from the patient in which it was
detected. A PCR product of the expected size was
detected in CD138+ tumor cells but not in the peripheral
blood mononuclear control [Fig. 3b (top)]. Re-sequencing
Fig. 1 Targeted sequencing identiﬁes chromosome-level, arm-
level, and focal CNVs. a Hyperdiploid and (b; arrow) focal copy
number events detected by CopyCat2 (blue; p < 0.05) from log2 ratios
of tumor to paired normal sequencing depth (y-axis) across
chromosomes (x-axis). (Clonal) single-copy gains occur at a log2 ratio
of log2(3/2) =0.58, whereas (clonal) heterozygous/single-copy losses
occur at a log2 ratio of log2(1/2)=−1
Table 1 Frequency of Translocations
Transloaction Frequency (%)
t(11;14) 14
t(4;14) 13
t(8;14) 7
t(6;14) 2
t(14;20) 2
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and mapping of the tumor-speciﬁc PCR product conﬁrmed
the reciprocal translocation spanned chromosomes 14 and
22. Small regions were deleted on both derivative chro-
mosomes and thus could be used to selectively amplify the
corresponding wild-type (WT) chromosomes. We designed
primers within these deleted regions and used them to
perform PCR ampliﬁcation, which conﬁrmed the retention
of one copy of each of the WT chromosomes in the tumor
sample [Fig. 3b (bottom)].
To search for additional IGLL5 translocations, we
relaxed our ﬁltering constraints and found a second
sample predicted by LUMPY to harbor a t(14;22) trans-
location, though no DNA was available for validation. The
validated t(14;22) translocation was predicted to juxtapose
the μ and 3’ enhancers (chr14:106032614–106167601)
with DERL3. Hence, we looked for evidence of over-
expression of DERL3 and other cancer-associated genes
within 1Mb of the predicted breakpoint on chromosome
22 (IGLL5, BCR, and SMARCB1) by examining RNA-seq
expression data from a partially overlapping set of 84 MM
patients. We found outlying expression of DERL3 in six of
these samples (exceeding 1.5× the FPKM interquartile
range), including the second sample with a putative t
(14;22) translocation (Fig. 3c; no expression data were
available for the sample harboring the validated translo-
cation). Additionally, we found that DERL3 was over-
expressed in MM relative to other cancer types within the
Cancer Cell Line Encyclopedia (CCLE)29 (Supplementary
Fig. 2 Targeted sequencing detects IGH and MYC translocations. Circos plots of (a) IGH and (b) MYC translocations. Chromosomes involved in
translocations are magniﬁed to highlight regions and genes near breakpoints. c Breakpoints (vertical lines) of canonical IGH translocations within IGH
locus. E3A2 and E3A1: 3’ enhancer elements downstream of IGHA2 and IGHA1 genes, respectively. Eμ: μ enhancer. Purple boxes: switch regions.
Figure is to scale
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Figure S5), with high expression also reported in other B-
cell malignancies. We also examined expression of IGLL5
both within our cohort and CCLE. IGLL5 expression was
in the 82nd percentile in the putatively translocated
sample for which we had RNA-seq data, though it is not
noticeably elevated with respect to the mean expression
(data not shown). IGLL5 expression in MM cell lines
within the CCLE is second only to Burkitt’s Lymphoma
cell lines; more generally, and as with DERL3, IGLL5
expression is higher in B-cell malignancies than in other
cancer types. Taken together, these data suggest that
DERL3 may be dysregulated in MM via IGH translocation
or another unknown mechanism.
Targeted capture sequencing identiﬁes intra- and inter-
chromosomal MYC translocations
FISH validation data of MYC translocations were not
available to tune LUMPY parameters and, as a result,
intra- and (non-IGH) inter-chromosomal MYC translo-
cations were called at a high false-positive rate (in every
tumor and normal sample, Supplementary Figure S6). To
accurately detect somatic MYC translocations, we devel-
oped a machine learning-based approach tuned to ﬁlter
putative MYC translocations called in normal samples.
Applying this method to tumor samples resulted in ﬁve
intra-chromosomal and two non-IGH inter-chromosomal
MYC translocations, with one sample having one intra-
and one inter-chromosomal translocation (6 of 95, 6%,
Fig. 2b; Supplementary Table S7). The intra-chromosomal
translocations involved neighboring genes PVT1 and
POU5F1B, as previously reported14.
Targeted capture sequencing identiﬁes non-silent single-
nucleotide variants in all tumor samples
All tumor samples harbored at least one somatic (mis-
sense, nonsense, or frame-shift) mutation, with each
sample having a mean of 20 mutations (Supplementary
Table S8). A total of 443 genes had a non-synonymous
(frame-shift insertion or deletion, missense, or nonsense)
mutation in one or more samples; 581 genes had a
mutation of any kind in one or more samples. Ninety-four
of 95 tumor samples had a mutation predicted to be
deleterious by Poly-Phen230 or SIFT31, with each sample
having a mean of twelve deleterious mutations. In 24
instances, we observed a gene harboring multiple muta-
tions previously associated with cancer (via COSMIC).
This occurred in thirteen samples across seventeen genes,
including KRAS and RB1; both were among the most
frequently observed (in three samples).
Increased sequencing depth yields few additional variants
To determine whether MM is characterized by deeply
subclonal variants of biological signiﬁcance, we performed
additional sequencing of 15 tumor (mean depth= 1,259×,
min= 506×, max= 1,660×) and paired normal (mean=
1,326×, min= 763×, max= 1,727×) samples. We then
compared the allele frequencies of variants discovered
during the original and/or subsequent deep sequencing
(Fig. 4). To focus on high-conﬁdence events likely to be of
biological relevance, we removed silent variants, those in
intronic, intergenic, or ﬂanking regions, those in IGH
(and, hence, likely arising due to somatic hypermutation),
or those that were ﬂagged as likely germline variants by at
least one caller in at least one study. This resulted in 57
variants in the original sequencing study (mean depth=
92×) and 67 variants in the subsequent study (mean
depth= 1,169×). Variant allele frequencies (VAFs) of
mutations shared across the two studies were highly
correlated (R2= 0.80; p < 2.2e-16). As expected, the vast
majority of variants unique to either study had low VAFs:
one of the four variants unique to the original study had a
VAF <10%, though all had an alternate allele count of
Fig. 3 IGLL5 is translocated and DERL3 is overexpressed in multiple myeloma. a Schematic of validated t(14;22) translocation. (Left) WT
chromosomes 14 and 22 with horizontal lines indicating location of breakpoints within the IGH and IGLL5 loci, respectively. (Right) Two derivative
(der) chromosomes, each retaining a portion of its respective IGH or IGLL5 gene. Cancer-associated genes within 1 Mb of breakpoint on der(14) are
shown. b PCR validation of t(14,22) translocation. Oligos speciﬁc to each breakpoint used in PCR reactions (top). Oligos speciﬁc to the small regions
deleted on der(14) and der(22) were designed to detect non-translocated allele (bottom). T tumor, N germline (peripheral blood) control. c DERL3
expression across 84 MM patients. Red circle indicates sample in which putative (non-validated) t(14;22) translocation was detected. FPKM Fragments
Per Kilobase of transcript per Million mapped reads
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three or fewer supporting reads, while 12 of the 14 var-
iants unique to the subsequent study had a VAF <10%.
Though relatively few new variants were discovered by the
additional sequencing, these did include several annotated
in COSMIC in genes KRAS, HECW1, and ZFHX4.
These results were recapitulated in a comparison of the
variants discovered in 44 samples subjected to capture-
based sequencing (mean depth of 1,562 capture-based
variants= 123×) and previously to exome sequencing
(mean depth of 3,563 exome variants= 136×; Supple-
mentary Figure S7). As in our above comparison, the
1,450 mutations discovered in both studies had highly
correlated VAFs (R2= 0.85; p < 2.2e-16). Again, the
majority of variants unique to one study had low VAF: 79
of 112 variants unique to the capture-based study (Sup-
plementary Fig. S7C) and 2,066 of the 2,113 variants
unique to the exome-based study (Supplementary Figure
S7B) had VAFs <10%.
Fig. 4 Greater sequencing depth yields few additional variants.
VAF of variants discovered during initial targeted sequencing (x-axis)
and/or with subsequent deeper sequencing (y-axis)
Fig. 5 Targeted sequencing identiﬁes CNVs, SNVs, and translocations. a Mutations per Mb, b SNVs, and c CNVs and translocations detected
across 95 samples (columns). MYC-ITX: intra-chromosomal MYC translocations; MYC-CTX: inter-chromosomal MYC translocations; Non MYC-IGH CTX:
inter-chromosomal IGH translocations, excluding those involving MYC
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To further explore the effects of sequencing depth, we
downsampled the sequencing reads from the 15 deeply-
sequenced samples, called variants on the downsampled
reads, and plotted the total number of variants following
ﬁltering (as above) in the downsampled and full data set
(Supplementary Figure S8). As expected, the number of
variants was correlated with sequencing depth (R2 = 0.52;
p = 10−3). However, beyond ~25% of the ﬁnal sequencing
depth (or a mean depth of ~300×), the increase in number
of discovered variants is marginal. Similar performance
was observed at an even lower depth of 92× in the
aforementioned case of the 15 original capture results
later re-sequenced. Together, these results indicate that
depths as low as 100× can capture the majority of variants
of interest and that coverage beyond 300× will lead to
sharply diminishing returns.
Targeted capture sequencing facilitates integrative
analysis across mutation types
Integrated analysis of CNVs, SNVs, and translocations
highlights patterns of mutual exclusivity and co-
occurrence both within and across mutation types
(Fig. 5). We tested for signiﬁcance of these patterns
after excluding the apparent hypermutator sample
(leftmost column; Fig. 5a) to improve statistical power.
This revealed mutation co-occurrence (blue; Fig. 6;
Table S9) within CNVs [i.e., of del(6q) with del(16q) and
amp(1q) and of del(13q) with amp(1q) and del(14q)]
and involving CNVs and translocations [i.e., of del(14q)
with t(4;14)]. As expected, we detected mutual exclu-
sivity (red; Fig. 6; Table S9) between hyperdiploidy and t
(11;14). We also detected cross-mutation type exclu-
sivity between CNVs and SNVs [i.e., both RAS muta-
tions (i.e., KRAS or NRAS) and FAM46C are mutually
exclusive with del(6q)]. IGLL5 was the third most fre-
quently mutated gene in our data set (Fig. 5b; 18%), with
(silent and non-synonymous) IGLL5 mutations enri-
ched for a c-AID signature (i.e., C to T/G mutation at
WRCY motifs; p= 2.7 × 10−6; binomial test). Thirty-
eight of the 40 detected IGLL5 SNVs occurred in amino
acid positions one to 100, outside of any annotated
protein domains. The remaining two (K166N and
K189R) occurred in the immunoglobulin C1-set
domain. Mutations in IGLL5 were mutually exclusive
of RAS mutations (p= 0.006), with trends toward
mutual exclusivity with KRAS (p= 0.054), NRAS (p=
0.111), and FAM46C (p= 0.113), independently (Figs 5
and 6). IGLL5 mutations in diploid loci had a median
VAF of 58% and a ﬁrst quartile VAF of 39%, suggesting
that the majority are likely clonal (Supplementary Fig-
ure S9). Finally, we found that IGLL5 SNVs are asso-
ciated with disease progression [Fig. 7; hazard ratio=
1.46 (95% conﬁdence interval: 1.03–2.08); p= 0.03 (log-
rank test)].
Discussion
We developed a MM-speciﬁc, capture-based sequen-
cing platform targeting 465 genes that detects CNVs,
SNVs, and translocations. We used the platform to
sequence 95 tumor/normal pairs and validated its ability
to detect SNVs and translocations using exome sequen-
cing and FISH data. After developing custom computa-
tional approaches for reducing false positives, we detected
Fig. 6 Targeted sequencing identiﬁes co-occurrence and mutual
exclusivity across mutation types. Co-occurring (blue) and mutually
exclusive (red) mutations (p < 0.05). Numbers indicate p-values
Fig. 7 IGLL5 mutations are associated with increased risk of
disease progression. Kaplan-Meier curves of IGLL5 mutant samples
(with non-synonymous SNVs and/or indels) versus IGLL5 WT samples
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CNVs (Fig. 1) and known IGH translocations at expected
frequencies (Fig. 2; Table 1) and discovered rare novel
chromosomal translocations (Fig. 3). By deeply sequen-
cing 15 pairs, we showed that there is a marginal increase
in number of non-silent variants discovered with
sequencing depth (Fig. 4). Hence, many scientiﬁc and
some clinical goals may be achievable with the more
modest sequencing depth (~100×) used for the complete
cohort of 95 pairs.
We detected (intra- and inter-chromosomal) MYC
translocations at a frequency of 13% [95% CI (7%-20%); 12
of 95; Fig. 2; Tables S5 and S7]. This is generally con-
sistent with prior studies, though a considerable range of
frequencies has been published. Such discrepancies are
likely due in part to differences in sample size, disease
stage, assay, and assay optimization/tuning. An early study
using FISH reported complex MYC abnormalities in 50%
of primary tumors—however, the analyzed samples were
few [7 of 14; 95% CI (26%-74%)] and advanced (stage
III)32. MYC translocation frequencies more similar to
those we observed have been detected in newly diagnosed
MM patients using both FISH—15% [79 of 529; 95% CI
(12%-18%)]33 and 23% [62 of 274; 95% CI (18%-
28%)]34,35—and a capture-based next-generation sequen-
cing approach similar to that presented here—20% [21 of
104; 95% CI (13%-28%)]14.
Our data revealed that IGLL5 is mutated via both point
substitutions and translocations in MM (Figs 2, 3 and 5).
The SNVs within the locus likely result from somatic
hypermutation of the immunoglobulin lambda light chain
locus, which spans IGLL5. Indeed, we saw an enrichment
for AID-induced mutations within IGLL5, as has been
previously observed in chronic lymphocytic leukemia
(CLL), where the gene is frequently mutated36. We found
that non-synonymous IGLL5 mutations are both mutually
exclusive with RAS mutations (Fig. 6) and associated with
disease progression (Fig. 7) and, with a median VAF of
58%, are likely present in the founding clone. Together,
these ﬁndings suggest that IGLL5 mutation may con-
tribute to myeloma pathogenesis, but without additional
data their functional signiﬁcance remains unknown. The
fact that mutations and translocations do not recurrently
affect speciﬁc residues in the IGLL5 protein supports a
loss of function model, but an alternative hypothesis is
that IGLL5mutations are simply a biomarker for high-risk
disease.
We observed that IGLL5 was translocated to the IGH
locus in two patient samples (Figs. 2 and 3). Transloca-
tions between IGH and either of the two light chain loci
have been reported in B cells and their associated dis-
orders: IGL/IGH translocations have been reported in
non-Hodgkin lymphoma37 and in activated B cells38
where it was suggested that the translocations resulted
from deﬁciencies in non-homologous end-joining that
induced both V(D)J-recombination-associated breaks at
the IGL locus and class switch recombination-associated
IGH breaks. The authors speculated that, since the
translocations conferred no obvious selective advantage,
these translocations simply reﬂected the mechanistic
opportunity presented by two frequently-broken and
spatially-proximal loci38. IGH translocations partnered
instead with IGK have been detected in B-cell lympho-
mas39 and in a patient-derived B lymphoblastoid cell
line40 with the latter plausibly attributable to the patient’s
prior, long-term treatment with a DNA-damaging alky-
lating agent. The possibility remains that the transloca-
tions we detected play a functional role by co-opting a
large super-enhancer downstream of IGLL5, which was
found to be active within the MM1.S MM cell line41. Its
position between IGLL5 and BCR place it on the der(14)
chromosome of the t(14;22) translocation we validated.
Hence, this super-enhancer may amplify the effect of the
IGH enhancers in upregulating the expression of nearby
genes translocated to chromosome 14. Indeed, we
observed upregulation of one such gene, DERL3, across
MM tumors relative to other cancer types, generally
(Supplementary Figure S5), and in the sample with the
second putative t(14;22) translocation, speciﬁcally (Fig. 3).
Overexpression of DERL3 could play a role in MM by
increasing endoplasmic reticulum (ER)-associated degra-
dation within the proteasome. DERL3 forms an export
channel in the ER through which misfolded proteins fated
for degradation reach the proteasome42. The proteasome
inhibitor bortezomib is highly efﬁcacious in MM cells.
Hence, were it to instead promote, rather than inhibit,
activity of the proteasome, DERL3 overexpression might
confer a selective advantage to MM cells. Future experi-
ments are required to decipher the importance of IGLL5
translocations and the signiﬁcance of DERL3
overexpression.
In addition to detecting known mutations, the plat-
form was designed to enable discovery: (1) We queried
465 genes, a much larger set than assayed by previous
targeted platforms6,11,16, and (2) we tiled across the
entire V, D, and J regions, as opposed to restricting
probes to annotated segments within these regions15 in
an attempt to detect translocations involving inter-
segment regions of the locus. Additional experience will
be necessary to evaluate these design decisions. For
example, lack of inferred translocations involving the J
region may suggest that probes used to tile across this
~700 Kb region are better invested elsewhere. In parti-
cular, future versions of the platform should provide
currently lacking coverage of chromosome arm Yq,
though the tandem-rich arms of acrocentric chromo-
somes (13p, 14p, 15p, 22p, and Yp) will remain difﬁcult
to capture. Additionally, targeting probes to common
SNPs would enable detection of allele-speciﬁc ploidy at
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a given locus43, which would facilitate SNV-based
inference of clonal evolution44.
Mutation4 and expression45 data, coupled with ISS
stage, have been shown to improve prognostic accuracy
over ISS stage alone. Indeed, two recent crowd-sourcing
competitions [a DREAM challenge (https://www.synapse.
org/#!Synapse:syn6187098/wiki/401884; refs46,47 and a
Topcoder challenge (http://crowdsourcing.topcoder.com/
myeloma_predictor)] aim to improve MM patient strati-
ﬁcation using genomic, transcriptomic/expression, cyto-
genetic, and clinical features. The ease of employing a
single platform to assay CNVs, SNVs, and translocations
would facilitate these and related efforts. Signiﬁcantly, the
same probes could be used to perform targeted RNA
sequencing, which would also furnish these studies with
comparative gene expression across samples.
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